The purpose of this study is to assess the drug levels of BMS-986166 in healthy male participants.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
7
Specified dose on specified days
Specified dose on specified days
Local Institution - 0001
Madison, Wisconsin, United States
Total amount of total radioactivity (TRA) recovered in urine (UR)
Time frame: Up to 90 days
Total amount of TRA recovered in feces (FR)
Time frame: Up to 90 days
Total amount of TRA recovered in urine and feces combined (RTotal)
Time frame: Up to 90 days
Percent of TRA recovered in urine (%UR)
Time frame: Up to 90 days
Percent of TRA recovered in feces (%FR)
Time frame: Up to 90 days
Percent of TRA recovered in urine and feces combined (%TOTAL)
Time frame: Up to 90 days
Maximum observed concentration (Cmax)
Time frame: Up to 89 days
Time of maximum observed concentration (Tmax)
Time frame: Up to 89 days
Area under the concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]
Time frame: Up to 89 days
Number of participants with adverse events (AEs)
Time frame: Up to 124 days
Number of participants with serious adverse events (SAEs)
Time frame: Up to 124 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of participants with vital sign abnormalities
Time frame: Up to 90 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 90 days
Number of participants with physical examination abnormalities
Time frame: Up to 90 days
Number of participants with clinical laboratory test abnormalities
Time frame: Up to 90 days
Maximum observed concentration (Cmax)
Time frame: Up to 89 days
Time of maximum observed concentration (Tmax)
Time frame: Up to 89 days
Area under the concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]
Time frame: Up to 89 days